276 related articles for article (PubMed ID: 19287976)
21. Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.
Zhao W; Wei L; Tan D; Su G; Zheng Y; He C; Mao ZJ; Singleton TP; Yin B
PLoS One; 2014; 9(10):e109198. PubMed ID: 25314317
[TBL] [Abstract][Full Text] [Related]
22. In vitro leukemia cell models of Ara-C resistance.
Funato T; Satou J; Nishiyama Y; Fujimaki S; Miura T; Kaku M; Sasaki T
Leuk Res; 2000 Jun; 24(6):535-41. PubMed ID: 10781689
[TBL] [Abstract][Full Text] [Related]
23. Synergisitic and Antagonistic AML Cell Type-specific Responses to 5-Aza-2-deoxycitidine and 1-h-D-Arabinofuranoside.
Elmoneim AA; Heuston E; Wai DH; Triche T; Arceci RJ
Anticancer Res; 2016 Feb; 36(2):691-6. PubMed ID: 26851026
[TBL] [Abstract][Full Text] [Related]
24. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
Jahns-Streubel G; Reuter C; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1995 Nov; 9(11):1857-63. PubMed ID: 7475275
[TBL] [Abstract][Full Text] [Related]
25. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside.
Flasshove M; Strumberg D; Ayscue L; Mitchell BS; Tirier C; Heit W; Seeber S; Schütte J
Leukemia; 1994 May; 8(5):780-5. PubMed ID: 7514246
[TBL] [Abstract][Full Text] [Related]
26. Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin.
Song JH; Kim SH; Kim HJ; Hwang SY; Kim TS
Int J Oncol; 2008 Apr; 32(4):931-6. PubMed ID: 18360721
[TBL] [Abstract][Full Text] [Related]
27. Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines.
Rathe SK; Largaespada DA
Leukemia; 2010 Aug; 24(8):1513-5. PubMed ID: 20508618
[No Abstract] [Full Text] [Related]
28. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
[TBL] [Abstract][Full Text] [Related]
29. Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.
Levin M; Stark M; Berman B; Assaraf YG
Cell Death Dis; 2019 May; 10(6):390. PubMed ID: 31101804
[TBL] [Abstract][Full Text] [Related]
30. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
31. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
Stegmann AP; Honders MW; Hagemeijer A; Hoebee B; Willemze R; Landegent JE
Ann Hematol; 1995 Jul; 71(1):41-7. PubMed ID: 7543292
[TBL] [Abstract][Full Text] [Related]
32. Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.
Galmarini CM; Clarke ML; Santos CL; Jordheim L; Perigaud C; Gosselin G; Cros E; Mackey JR; Dumontet C
Int J Cancer; 2003 Oct; 107(1):149-54. PubMed ID: 12925971
[TBL] [Abstract][Full Text] [Related]
33. Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
Candelaria M; Corrales-Alfaro C; Gutiérrez-Hernández O; Díaz-Chavez J; Labardini-Méndez J; Vidal-Millán S; Herrera LA
Chemotherapy; 2016; 61(6):313-8. PubMed ID: 27119162
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.
Lamba JK; Crews K; Pounds S; Schuetz EG; Gresham J; Gandhi V; Plunkett W; Rubnitz J; Ribeiro R
J Pharmacol Exp Ther; 2007 Dec; 323(3):935-45. PubMed ID: 17855478
[TBL] [Abstract][Full Text] [Related]
35. Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells.
Veuger MJ; Heemskerk MH; Honders MW; Willemze R; Barge RM
Blood; 2002 Feb; 99(4):1373-80. PubMed ID: 11830489
[TBL] [Abstract][Full Text] [Related]
36. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
Jin G; Matsushita H; Asai S; Tsukamoto H; Ono R; Nosaka T; Yahata T; Takahashi S; Miyachi H
Biochem Biophys Res Commun; 2009 Dec; 390(3):1001-6. PubMed ID: 19853583
[TBL] [Abstract][Full Text] [Related]
37. HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
Chen L; Hu N; Wang C; Zhao H
Arch Biochem Biophys; 2020 Feb; 680():108244. PubMed ID: 31904363
[TBL] [Abstract][Full Text] [Related]
38. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
Hubeek I; Stam RW; Peters GJ; Broekhuizen R; Meijerink JP; van Wering ER; Gibson BE; Creutzig U; Zwaan CM; Cloos J; Kuik DJ; Pieters R; Kaspers GJ
Br J Cancer; 2005 Dec; 93(12):1388-94. PubMed ID: 16333246
[TBL] [Abstract][Full Text] [Related]
39. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
40. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.
Taub JW; Huang X; Matherly LH; Stout ML; Buck SA; Massey GV; Becton DL; Chang MN; Weinstein HJ; Ravindranath Y
Blood; 1999 Aug; 94(4):1393-400. PubMed ID: 10438727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
